Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17436872 | SILICIFIED IMMUNOGENIC CELLS, METHODS OF MAKING, AND METHODS OF USING | September 2021 | October 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 17256527 | MITOCHONDRIAL AUGMENTATION THERAPY OF OCULAR DISEASES | December 2020 | November 2024 | Allow | 46 | 1 | 0 | No | No |
| 17253046 | CELL | December 2020 | January 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17051461 | THREE-DIMENSIONAL CULTURE METHOD, THREE-DIMENSIONAL CULTURE STRUCTURE, AND THREE-DIMENSIONAL CULTURE STRUCTURE MANUFACTURING METHOD | October 2020 | November 2024 | Abandon | 48 | 2 | 1 | Yes | No |
| 17050741 | MYOSIN 15 PROMOTERS AND USES THEREOF | October 2020 | September 2024 | Allow | 47 | 0 | 1 | Yes | No |
| 17047990 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | October 2020 | June 2025 | Allow | 56 | 1 | 1 | Yes | No |
| 17066378 | METHOD OF ASSESSING WOUND HEALING POTENCY OF A MESENCHYMAL STEM POPULATION AND RELATED METHODS OF SELECTING MESENCHYMAL STEM CELLS AND IDENTIFYING TISSUE AS STARTING MATERIAL FOR PRODUCING A MESENCHYMAL STEM CELL POPULATION | October 2020 | June 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 16978800 | RECOMBINANT ADENO-ASSOCIATED VIRUSES ENCODING SERPIN PEPTIDES AND USES THEREOF | September 2020 | December 2024 | Allow | 51 | 2 | 1 | No | No |
| 16965226 | DEVICE FOR PRODUCING GLOBULES OF ADIPOSE TISSUE | July 2020 | September 2024 | Allow | 50 | 2 | 0 | Yes | No |
| 16957896 | CELL POPULATION INCLUDING ADHESIVE STEM CELLS, PRODUCTION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION | June 2020 | September 2024 | Allow | 51 | 1 | 1 | Yes | No |
| 16894569 | GENERATION OF FUNCTIONAL NEUTROPHILS AND MACROPHAGES FROM INDUCED PLURIPOTENT STEM CELLS IN CHEMICALLY DEFINED CONDITIONS USING TRANSIENT EXPRESSION OF ETV2 | June 2020 | May 2025 | Allow | 59 | 3 | 1 | No | No |
| 16568707 | HUMAN HOMOGENEOUS AMNIOTIC FLUID STEM CELL LINES AND USES THEREOF | September 2019 | November 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16479297 | APPARATUS AND METHODS FOR IN VITRO PRECLINICAL HUMAN TRIALS | July 2019 | February 2025 | Allow | 60 | 2 | 1 | No | No |
| 15771781 | METHOD FOR PRODUCING CELL POPULATION COMPRISING MESENCHYMAL STEM CELLS, MESENCHYMAL STEM CELLS, CELL POPULATION, AND PHARMACEUTICAL COMPOSITION | April 2018 | January 2025 | Abandon | 60 | 6 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner RAHMAN, MASUDUR works in Art Unit 1633 and has examined 14 patent applications in our dataset. With an allowance rate of 78.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 56 months.
Examiner RAHMAN, MASUDUR's allowance rate of 78.6% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by RAHMAN, MASUDUR receive 2.29 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by RAHMAN, MASUDUR is 56 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -2.2% benefit to allowance rate for applications examined by RAHMAN, MASUDUR. This interview benefit is in the 9% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 27.8% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 18.2% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.